A Third Kidney-Protective Drug for a Patient Whose Diabetes Is Already Controlled
A diabetic CKD patient's eGFR keeps falling despite two proven kidney-protective drugs already at work. A third could help, per genuinely new trial evidence — but her blood sugar is already at goal, and the drug she'd be adding is one she's already said she's reluctant to take.
Her arthritic hands are, as usual, the first thing Miriam K. mentions at every visit, a small ritual nephrology has come to expect and that has nothing to do with today's actual question. She is a 63-year-old woman who has run the same alterations shop out of her home for over twenty years, precise handwork made harder by that arthritis. Her type 2 diabetes, twelve years in, is well controlled — HbA1c 7.0% on metformin — and her CKD has been managed with lisinopril at maximum tolerated dose and dapagliflozin for the past two years. Despite both drugs doing real, measurable work, her eGFR has continued falling, from 45 to 38 over the last eighteen months, with her UACR still elevated at 540 mg/g.
Semaglutide is the newest candidate for a third layer of kidney protection, and the case for it is no longer built on its glucose-lowering effect at all — Miriam's diabetes is already controlled without it. FLOW, the trial that actually tested this, randomized patients with type 2 diabetes and CKD, many already on background RAAS inhibitor and a growing share on SGLT2 inhibitor therapy, to semaglutide or placebo, and found a significant reduction in the composite outcome of kidney-disease progression, kidney failure, and cardiovascular or kidney-related death — strong enough that the trial stopped early for efficacy. That benefit tracked independent of glycemic status, which is why the drug's kidney indication is written separately from its diabetes indication. What complicates the conversation is that Miriam has said plainly, before this visit even started, that she is reluctant about both the injection itself and the nausea she's heard it can cause.
A real kidney-protective benefit, and a patient who's already said no to the format
I'd recommend adding semaglutide. FLOW specifically tested this in patients with type 2 diabetes and CKD, many already on background RAAS inhibition and a growing share on SGLT2 inhibitors, and found a significant reduction in the composite of kidney-disease progression, kidney failure, and cardiovascular or kidney death — strong enough the trial stopped early for efficacy. That benefit tracked independent of glycemic control, which matters directly here since her A1c is already fine. Her eGFR is still falling despite two proven agents; this is a real third option, not a hopeful one.
I don't dispute the trial data, but I want to be careful here — this isn't a necessity the way her ACE inhibitor or SGLT2 inhibitor are. Her diabetes doesn't need it. She told us plainly, before we even started today's visit, that she's reluctant about the injection and worried about nausea. That's a real quality-of-life cost for an elective addition, and I think her stated preference deserves real weight, not a recommendation that talks past it.
I'm not saying the kidney benefit isn't real — I'm saying "real benefit" and "she should take it" aren't automatically the same conclusion when she's already told us how she feels about it.
Both things can be true — the benefit is real, and her reluctance deserves to shape how we offer it, not whether we offer it at all. Starting at the lowest available dose with slow titration specifically reduces the nausea that drives most early discontinuation, and framing this explicitly as a trial she can stop, not a commitment, respects what she's already told us while still giving the kidney-protective benefit a real chance to matter. The decision stays hers either way.
Agreed: semaglutide offered as an explicit trial at the lowest dose, framed around Miriam's own stated concerns rather than around the trial's headline result alone, with the final decision left to her.
Not resolved as a general policy: how the team should frame genuinely elective, kidney-specific benefit therapies going forward when a patient has already expressed reluctance before the conversation starts — handled here case by case rather than as a settled approach.